Table 1– Baseline demographics and disease characteristics
PlaceboGolimumabUstekinumabTotal
Total patients#585560173
 Age mean±sd years49.5±9.550.0±9.449.8±10.249.8±9.7
 Male29 (50.0)28 (50.9)31 (51.7)88 (50.9)
 Ethnicity
  White32 (55.2)36 (65.5)38 (63.3)106 (61.3)
  Black or African American23 (39.7)16 (29.1)19 (31.7)58 (33.5)
  Asian01 (1.8)01 (0.6)
  Other1 (1.7)2 (3.6)2 (3.3)5 (2.9)
  Unknown1 (1.7)001 (0.6)
  Multiple1 (1.7)01 (1.7)2 (1.2)
 Weight mean±sd kg88.7±20.487.9±19.392.2±21.589.6±20.4
Lung group#
 Patients444246132
 FVC L2.692.842.622.72
 FVC % predicted68.468.064.366.9
 FEV1 L1.831.891.821.84
 FEV1 % predicted57.657.055.956.8
DLCO (mL·min−1·mmHg−1)13.210.312.612.1
 SGRQ total score53.151.150.251.4
 6MWD m389.5401.9396.0395.7
  • Data presented as n or n (%), unless otherwise stated. FVC: forced vital capacity; FEV1: Forced expiratory volume in 1 s; DLCO: diffusing capacity of the lung for carbon monoxide; SGRQ: St George's Respiratory Questionnaire; 6MWD: 6-min walking distance. #: patients were randomised.